12 Best Ginkgo Bioworks Alternatives & Competitors (2026)

Recursion Pharmaceuticals runs one of the largest automated wet-lab-plus-AI platforms, generating millions of cellular images to map disease biology. Its strength lies in scale of phenotypic screening and an advancing clinical pipeline. Compared with Algen Biotechnologies, Recursion is less focused on CRISPR gene modulation and more on high-content imaging; both companies pursue big-pharma partnerships but Recursion is already public with broader disease coverage.

Recursion Pharmaceuticals runs one of the largest automated wet-lab-plus-AI platforms, generating millions of cellular images to map disease biology. Its strength lies in scale of phenotypic screening and an advancing clinical pipeline. Compared with Algen Biotechnologies, Recursion is less focused on CRISPR gene modulation and more on high-content imaging; both companies pursue big-pharma partnerships but Recursion is already public with broader disease coverage.

BASF develops and commercializes bio-based acrylic acid through internal R&D and partnerships. It has pilot-scale renewable acrylic acid and large existing petrochemical capacity. Compared with Industrial Microbes, BASF can supply both bio and conventional grades at global scale but has less emphasis on third-party strain licensing.

Ginkgo Bioworks operates a large foundry that designs custom microbes for chemicals, materials, and ingredients. It offers end-to-end organism engineering and scale-up support rather than a pre-built acrylic acid package. Compared with Industrial Microbes, Ginkgo provides broader molecule flexibility but requires longer program timelines and higher upfront fees for custom strain development.

Insilico Medicine applies generative AI and reinforcement learning primarily to small-molecule design, moving from target to IND in record time for several programs. Unlike Algen’s CRISPR-driven functional genomics, Insilico starts from omics data and chemistry engines. It offers lower upfront costs via software licensing but lacks Algen’s wet-lab gene-modulation datasets and Doudna-derived precision editing capabilities.

Exscientia combines patient tissue data with generative design to create precision medicines, emphasizing rapid design-make-test cycles. Its platform is chemistry-centric rather than CRISPR-centric. Relative to Algen Biotechnologies, Exscientia provides stronger early chemistry optimization but weaker direct causal gene-to-phenotype mapping at single-cell resolution.

Atomwise applies deep learning to structure-based virtual screening for small molecules. It provides rapid hit identification without wet-lab gene modulation. Relative to Algen, Atomwise is chemistry-first and lower cost for early screening but cannot replicate the causal biology resolution delivered by AlgenCRISPR and AlgenBrain.

CRISPR Therapeutics develops clinical gene-editing therapies using CRISPR-Cas systems. While sharing foundational CRISPR IP with Algen, its emphasis is on therapeutic editing rather than discovery platforms. Companies seeking Algen-style target identification would find CRISPR Therapeutics less relevant for AI-driven causal biology mapping.

Genomatica develops fermentation processes that convert sugars into bio-based chemicals including 1,4-butanediol and acrylic acid precursors. It has reached commercial-scale partnerships and focuses on cost-competitive drop-in molecules. Versus Industrial Microbes, Genomatica emphasizes sugar feedstocks and has more published commercial volume data, while Industrial Microbes highlights ethanol and methane routes.

Tempus aggregates clinical and molecular patient data to power precision medicine and target discovery. Its strength is real-world evidence rather than experimental CRISPR perturbation data. Compared with Algen Biotechnologies, Tempus offers broader oncology datasets but fewer functional genomics screens for causal RNA signaling inference.

BenevolentAI mines literature and omics with knowledge graphs to surface drug targets and mechanisms. It has secured large pharma deals similar to Algen’s AstraZeneca partnership. However, Benevolent relies more on existing data than Algen’s proprietary high-throughput CRISPR modulation screens, resulting in different strengths for target validation versus de novo causal biology discovery.